A research association in Arizona hopes that the combination of two well-established drugs will reduce the disease in patients in the Phoenix area who are hospitalized for COVID-19.
A local clinical trial seeks to enroll 25 patients through the Scottsdale HonorHealth Hospital system for treatment trials, which is a mixture of azithromycin antibiotics and the antimalarial drug Atofacone, also known as Mepron.
The essay is a partnership between the translated Genomic Research Institute, HonorHealth, and the HonorHealth Research Institute.
Start smart today. Receive all the news you need in your inbox every morning.
Atovaquone should not be confused with hydroxychloroquine and chloroquine, two other antimalarial drugs that have been promoted as potential treatments for COVID-19.
Hydroxychloroquine and chloroquine have been used with mixed results, as these medications can cause heart problems in some patients. The US Food and Drug Administration. USA Warns against the use of hydroxychloroquine or chloroquine for COVID-19 outside of a hospital or clinical trial, signaling the risk of heart problems.
For more important stories: click here to subscribe to azcentral.com.
The researchers in an association say that the combination of atofacon and azithromycin has the advantage of reducing the risk of cardiac side effects compared to other possible COVID-19 treatments.
These two drugs have already received approval from the US Food and Drug Administration. USA To use them together as a treatment for a parasite called PapSiosis, which is caused by microscopic parasites and can be transmitted by ticks.
Research partners are testing COVID-19 treatment for “moderate to severe disease”. The first patient was registered on April 29.
The drug combination is one of several possible treatments for COVID-19, which are caused by new coronaviruses. Many hospitals across the country, including locations in Arizona, use the plasma of people who have recovered from COVID-19 to treat patients with respiratory illnesses.